Consensus on dignosis for ALK positive non-small cell lung cancer in China, the 2013 version

Chinese Journal of Pathology

Volumn 42, Issue 6, 2013, Pages 402-406

  Zhang, Xu Chao ^a   Lu, Shun ^a   Zhang, Li ^a   Wang, Chang Li ^a   Cheng, Ying ^a   Li, Gan Di ^a   Tony, Mok ^a   Huang, Cheng ^a   Liu, Xiao Qing ^a   Wang, Jie ^a   Wang, Meng Zhao ^a   Zhang, Yi Ping ^a   Zhou, Jian Ying ^a   Zhou, Xiao Yan ^a   Lin, Dong Mei ^a   Yang, Jin Ji ^a   Li, Hui ^a   Chen, Hai Quan ^a   Zhong, Wen Zhao ^a   Wu, Yi Long ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EML4 ALK FUSION PROTEIN, HUMAN; EML4-ALK FUSION PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN TYROSINE KINASE;

ARTICLE; CHINA; CONSENSUS; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; POLYMERASE CHAIN REACTION;

CARCINOMA, NON-SMALL-CELL LUNG; CHINA; CONSENSUS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; ONCOGENE PROTEINS, FUSION; POLYMERASE CHAIN REACTION; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84880421221     PISSN: 05295807     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0529-5807.2013.06.012     Document Type: Article

References (26)

1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 2007, 448(7153):561-566.
2. Wong DW, Leung EL, So KK, et al. The EML4 - ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer, 2009, 115(8):1723-1733.
3. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol, 2009, 27(26):42474253.
4. Shaw AT. Phase 3 randomized study of crizotinib versus pemetrexed or docetaxel chemotherapy in advanced, ALK-positive NSCLC (PROFILE 1007). 35th ESM0, 2012, abstract LBA1.
5. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell, 2007, 131(6):1190-1203.
6. Mitsudomi T, Suda K, Tomizawa K, et al. Clinico-pathologic features of lung cancer with EML4-ALK translocation. J Clin 0ncol, 2010(suppl):abstr 10598.
7. Zhang X, Zhang S, Yang X, et al. Fusion of EML4 and ALK is associated with de\elopment of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer, 2010, 9:188.
8. Wu SG, Kuo YW, Chang YL, et al. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wildtype EGFR. J Thorac Oncol, 2012, 7(1):98-104.
9. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res, 2009, 15(16):5216-5223.
10. Camidge DR, Kono SA, Flacco A, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res, 2010, 16(22):5581-5590.
11. Martelli MP, Sozzi G, Hernandez L, et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol, 2009, 174(2):661-670.
12. Boland JM, Erdogan S, Vasmatzis G, et al. Anaplastic lymphoma kinase immunoreactivity correlated with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol, 2009, 40(8):1152-1158.
13. Vysis ALK break apart FISH probe kit protocol. [2013-03-30]. http=//www.abbottmolecular.com/static/cms-workspace/pdfs/US/Vysis-ALK-FISH- Probe-Kit-PI.pdf
14. Sun JM, Choi YL, Won JK, et al. A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-Negative ALK. J Thorac Oncol, 2012, 7(12):e36-e38.
15. Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res, 2010, 16(5):1561-1571.
16. Park HS, Lee JK, Kim DW, et al. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer, 2012, 77(2):288-292.
17. McLeer-Florin A, Moro-Sibilot D, Melis A, et al. Dual 1HC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J Thorac Oncol, 2012, 7(2):348-354.
18. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Eng J Med, 2010, 363(18):1693-1703.
19. Yi ES, Boland JM, Maleszewski JJ, et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma; IHC score algorithm for FISH. J Thorac Oncol, 2011, 6(3):459465.
20. Paik JH, Choe G, Kim H, et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in nonsmall cell lung cancer; correlation with fluorescence in situ hybridization. J Thorac Oncol, 2011, 6(3):66472.
21. Han X, Ma L, Liu Y, et al. Assessment of alk rearrangement in advanced non-small cell lung cancer using fluorescence in situ hybridization & immunohistochemistry. 35th ESMO, 2012, abstract 1196P.
22. Iwahara T, Fujimoto J, Wen D, et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene, 1997, 14(4):439449.
23. VENTANA anti-ALK (D5F3) rabbit monoclonal primary antibody protocol. [2013-03-30]. http=//www.ventana.com
24. Tuononen K, Sarhadi VK, Wirtanen A, et al. Targeted resequencing reveals ALK fusion in non-small cell lung carcinomas detected by FISH, immunohistochemistry, and Real-Time RT-PCR; a comparison of four methods. Biomed Res Int, 2013, In press.
25. Lee JK, Kim TM, Koh Y, et al. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. Lung Cancer, 2012, 77(2):460463.
26. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol, 2013, In press.